1. Search Result
Search Result
Results for "

degenerative disease

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

3

Screening Libraries

1

Inhibitory Antibodies

2

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123936

    NF-κB IKK Neurological Disease Inflammation/Immunology
    SR12343, an IKK/NF-κB inhibitor, is a NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic. SR12343 inhibits TNF-α- and LPS-induced NF-κB activation by blocking the interaction between IKKβ and NEMO, with an IC50 of 37.02 μM for TNF-α-mediated NF-κB activation. SR12343 suppresses LPS-induced acute pulmonary inflammation in mice. SR12343 can be used for research of inflammatory and degenerative diseases .
    SR12343
  • HY-W009706

    Allopydin; W-7320

    Prostaglandin Receptor Inflammation/Immunology
    Alclofenac (Allopydin) is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac is a prostaglandin H2 synthase inhibitor. Alclofenac can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research .
    Alclofenac
  • HY-169557

    CDK Neurological Disease
    CDKI-IN-1 (Compound SNX12) is a cyclin-dependent kinase inhibitor (CDKI) inhibitor that can be used for research into degenerative diseases of the central nervous system .
    CDKI-IN-1
  • HY-161578

    Others Neurological Disease
    Dithio-CN03 is a compound with the highest neuroprotective efficacy. Dithio-CN03 fights the progression of retinitis pigmentosa (RP) by inhibiting the cGMP mediated signaling pathway and reducing photoreceptor cell death. Dithio-CN03 can be used in research into RP and other retinal degenerative diseases .
    Dithio-CN03
  • HY-143582

    Phosphodiesterase (PDE) Cancer
    ATX inhibitor 9 is a potent inhibitor of ATX. ATX inhibitor 9 is a thickened heteroaryl derivatives compound. Autotaxin (ATX), also known as ENPP2, is a secreted enzyme that is highly expressed mainly in cancer cells, bronchial epithelial cells and alveolar macrophages in the lung. ATX inhibitor 9 has the potential for the research of cancer or fibrous degenerative disease (extracted from patent WO2021078227A1, compound 3) .
    ATX inhibitor 9
  • HY-W408830

    Biochemical Assay Reagents Others
    4-Iodobutyl benzoate is structurally related to bicyclic heterocycles such as indole and indoline. 4-Iodobutyl benzoate is a metabolite of the drug amide and is used in the treatment of inflammatory bowel disease, degenerative diseases, and bowel disease.
    4-Iodobutyl benzoate
  • HY-129688

    Cholecystokinin Receptor Neurological Disease
    Sut-8701 is a Cholecystokinin (HY-P2932) analog that effectively slows the degenerative process of Alzheimer's disease by protecting the integrity of cholinergic neurons in the nucleus basalis .
    Sut-8701
  • HY-P99820

    NV-01

    TNF Receptor Inflammation/Immunology
    Ranevetmab (NV-01) is a caninised anti-NGF monoclonal antibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain .
    Ranevetmab
  • HY-174719

    mRNA Inflammation/Immunology
    Human ELANE mRNA encodes the human elastase (ELANE) protein, a member of serine proteases family. ELANE may play a role in degenerative and inflammatory diseases through proteolysis of collagen-IV and elastin.
    Human ELANE mRNA
  • HY-W009706A

    Allopydin sodium; W-7320 sodium

    Prostaglandin Receptor Inflammation/Immunology
    Alclofenac sodium is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac sodium is a prostaglandin H2 synthase inhibitor. Alclofenac sodium can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research .
    Alclofenac sodium
  • HY-W009706B

    Allopydin (lysinate); W-7320 (lysinate)

    Prostaglandin Receptor Inflammation/Immunology
    Alclofenac lysinate is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac lysinate is a prostaglandin H2 synthase inhibitor. Alclofenac lysinate can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research .
    Alclofenac (lysinate)
  • HY-135808

    NF-κB Inflammation/Immunology
    BIZ 114 (Example 11) is a fatty acid derivative and potent inhibits the TNF-α activated NF-κΒ pathway. BIZ 114 has the potential to prevent and / or treat ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases .
    BIZ 114
  • HY-106583

    Cinnoxicam; SPA-S-510; Sinartol

    COX Inflammation/Immunology
    Piroxicam cinnamate (Cinnoxicam) is a cyclooxygenase (COX) inhibitor, with anti-inflammatory activity. Piroxicam cinnamate is stable under gastric conditions, can be used for inflammatory-degenerative osteoarticular diseases, rheumatic disorders, and varicocele (VC) associated oligoasthenospermia research .
    Piroxicam cinnamate
  • HY-119447

    COX Inflammation/Immunology
    Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs .
    Mavacoxib
  • HY-148187

    NOD-like Receptor (NLR) Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases .
    NLRP3-IN-11
  • HY-119447S

    Isotope-Labeled Compounds COX Inflammation/Immunology
    Mavacoxib-d4 is the deuterium labeled Mavacoxib. Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs .
    Mavacoxib-d4
  • HY-119447R

    COX Inflammation/Immunology
    Mavacoxib (Standard) is the analytical standard of Mavacoxib. This product is intended for research and analytical applications. Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs .
    Mavacoxib (Standard)
  • HY-13027
    DAPT
    Maximum Cited Publications
    122 Publications Verification

    GSI-IX

    Organoid γ-secretase Amyloid-β Autophagy Notch Apoptosis Neurological Disease Inflammation/Immunology Cancer
    DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and 42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment .
    DAPT
  • HY-121971

    Endogenous Metabolite Cancer
    PMPMEase-IN-2 is an inhibitor of polyprenylated protein methylesterase, which has the activity of regulating polyprenylated protein metabolism. The regulation of PMPMEase-IN-2 is essential for maintaining normal cell survival. The abnormal activity of PMPMEase-IN-2 may be associated with degenerative diseases and cancer. Specific inhibitors of PMPMEase-IN-2 may have potential application value in inhibiting cancer .
    PMPMEase-IN-2
  • HY-34758
    N-Nitroso-N-methylurea
    10+ Cited Publications

    DNA Alkylator/Crosslinker Cancer
    N-Nitroso-N-methylurea (NMU;MNU;NMH) is a potent carcinogen, mutagen and teratogenand. N-Nitroso-N-methylurea is a direct-acting alkylating agent that interacts with DNA. N-Nitroso-N-methylurea targets multiple animal organs to cause various cancer and/or degenerative disease. N-Nitroso-N-methylurea is also a precursor in the synthesis of diazomethane .
    N-Nitroso-N-methylurea
  • HY-134928

    A2E

    Apoptosis Autophagy Reactive Oxygen Species (ROS) Cancer
    Pyridinium bisretinoid A2E (A2E) is a fluorophore that can be isolated from lipofuscin in the retinal pigment epithelium (RPE). Pyridinium bisretinoid A2E is an initiator of blue-light-induced apoptosis. Photoactivation of Pyridinium bisretinoid A2E mediates autophagy and the production of reactive oxygen species. Pyridinium bisretinoid A2E can be used in the study of retinal degenerative diseases .
    Pyridinium bisretinoid A2E
  • HY-134928A

    A2E TFA; N-retinylidene-N-retinylethanolamine TFA

    Apoptosis Autophagy Reactive Oxygen Species (ROS) Cancer
    Pyridinium bisretinoid A2E (A2E) TFA is a fluorophore that can be isolated from lipofuscin in the retinal pigment epithelium (RPE). Pyridinium bisretinoid A2E TFA is an initiator of blue-light-induced apoptosis. Photoactivation of Pyridinium bisretinoid A2E TFA mediates autophagy and the production of reactive oxygen species. Pyridinium bisretinoid A2E TFA can be used in the study of retinal degenerative diseases .
    Pyridinium bisretinoid A2E TFA
  • HY-102052

    Potassium Channel Metabolic Disease
    DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia .
    DCEBIO
  • HY-34758R

    DNA Alkylator/Crosslinker Cancer
    N-Nitroso-N-methylurea (Standard) is the analytical standard of N-Nitroso-N-methylurea. This product is intended for research and analytical applications. N-Nitroso-N-methylurea (NMU;MNU;NMH) is a potent carcinogen, mutagen and teratogenand. N-Nitroso-N-methylurea is a direct-acting alkylating agent that interacts with DNA. N-Nitroso-N-methylurea targets multiple animal organs to cause various cancer and/or degenerative disease. N-Nitroso-N-methylurea is also a precursor in the synthesis of diazomethane .
    N-Nitroso-N-methylurea (Standard)
  • HY-W717139

    Isotope-Labeled Compounds DNA Alkylator/Crosslinker Cancer
    N-Nitroso-N-methylurea-d5 is the deuterium labeled N-Nitroso-N-methylurea (HY-34758). N-Nitroso-N-methylurea (NMU;MNU;NMH) is a potent carcinogen, mutagen and teratogenand. N-Nitroso-N-methylurea is a direct-acting alkylating agent that interacts with DNA. N-Nitroso-N-methylurea targets multiple animal organs to cause various cancer and/or degenerative disease. N-Nitroso-N-methylurea is also a precursor in the synthesis of diazomethane .
    N-Nitroso-N-methylurea-d5
  • HY-118948

    Bcl-2 Family Neurological Disease
    MSN-50 is a Bax and Bak oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection .
    MSN-50
  • HY-118041

    Carboxylesterase (CES) Endogenous Metabolite Cancer
    PMPMEase-IN-1 is an allylated methylated protein methylesterase inhibitor with the property of inhibiting PMPMEase activity. PMPMEase-IN-1 may provide a useful strategy for cancer inhibition by enhancing its affinity for polyisoprenyl derivatives. PMPMEase-IN-1 showed the potential to have an effective concentration (EC50) value in causing degeneration of human neuroblastoma SH-SY5Y cells. Specific inhibition of PMPMEase-IN-1 may help regulate the metabolism of polyisoprenyl proteins and thus maintain normal cell survival. Further development and application of PMPMEase-IN-1 may open up new avenues for inhibiting degenerative diseases and cancer .
    PMPMEase-IN-1
  • HY-N0696
    Sipeimine
    2 Publications Verification

    Imperialine

    PI3K NF-κB Akt NOD-like Receptor (NLR) Pyroptosis Ferroptosis Inflammation/Immunology
    Sipeimine (Imperialine) is an inhibitor targeting the PI3K/AKT/NF-κB pathway and NLRP3 inflammasome, which can competitively bind to PI3K and p65. Sipeimine inhibits PI3K/AKT phosphorylation, blocks NF-κB nuclear translocation and NLRP3 inflammasome activation. Sipeimine exerts anti-inflammatory activities, inhibits pyroptosis and ferroptosis, and protects the extracellular matrix. Sipeimine can reduce cartilage degradation and synovial inflammation in osteoarthritis and improve PM2.5-induced lung injury. Sipeimine is mainly used in the study of anti-inflammatory and degenerative diseases .
    Sipeimine
  • HY-N0696R

    Imperialine (Standard)

    Reference Standards PI3K NF-κB Akt NOD-like Receptor (NLR) Pyroptosis Ferroptosis Inflammation/Immunology
    Sipeimine (Standard) is the analytical standard of Sipeimine (HY-N0696R). Sipeimine (Imperialine) is an inhibitor targeting the PI3K/AKT/NF-κB pathway and NLRP3 inflammasome, which can competitively bind to PI3K and p65. Sipeimine inhibits PI3K/AKT phosphorylation, blocks NF-κB nuclear translocation and NLRP3 inflammasome activation. Sipeimine exerts anti-inflammatory activities, inhibits pyroptosis and ferroptosis, and protects the extracellular matrix. Sipeimine can reduce cartilage degradation and synovial inflammation in osteoarthritis and improve PM2.5-induced lung injury. Sipeimine is mainly used in the study of anti-inflammatory and degenerative diseases .
    Sipeimine (Standard)
  • HY-12875

    Ras Cancer
    BQU57 is a selective inhibitor of RalA/RalB small GTPases, with a binding potency (Kb) of 7.7 μM for RalB-GDP. BQU57 can block its interaction with effector proteins (such as SEC5 and EXO84), inhibiting tumor cell migration, invasion and non-adherent growth. BQU57 downregulates the NF-κB signaling pathway, reduces the expression of IL-6, IL-8 and MMP-13, and inhibits apoptosis by regulating the Bcl-2/Bax balance. BQU57 also protects the extracellular matrix by inhibiting the Ral/NF-κB pathway and can be used for the study of degenerative diseases. BQU57 exhibits significant antitumor activity in triple-negative breast cancer (TNBC) models, inhibiting orthotopic tumor growth and lung metastasis and enhancing paclitaxel chemotherapy sensitivity .
    BQU57

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: